MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Home・Akcijų sąrašas・Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

74.82 -0.4

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

74.38

Max

74.84

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-100M -229M
Pardavimai	46M 203M
Pelno marža	-112.808
Darbuotojai	1,402
EBITDA	4.7B 4.6B

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+29.95% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-04-29

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-1.7B 12B
Ankstesnė atidarymo kaina	75.22
Ankstesnė uždarymo kaina	74.82

Naujienos nuotaikos

By Acuity

50%

166 / 349 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Neutral Evidence

29.78 / 33.645 Palaikymas ir pasipriešinimas

Ionis Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-02 17:11; UTC

Pagrindinės rinkos jėgos

Svarbiausios naujienos

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2026-04-02 17:10; UTC

Svarbiausios naujienos

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

2026-04-03 00:00; UTC

Svarbiausios naujienos

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2026-04-02 23:47; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2026-04-02 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2026-04-02 21:01; UTC

Svarbiausios naujienos

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2026-04-02 20:59; UTC

Įsigijimai, susijungimai, perėmimai

Starbucks and Boyu Capital Finalize China JV

2026-04-02 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-02 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-02 20:41; UTC

Uždarbis

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026-04-02 20:32; UTC

Rinkos pokalbiai

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2026-04-02 20:30; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 20:09; UTC

Rinkos pokalbiai

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2026-04-02 20:01; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 19:46; UTC

Rinkos pokalbiai

Is Oil the New GameStop? -- Market Talk

2026-04-02 19:35; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2026-04-02 19:29; UTC

Įsigijimai, susijungimai, perėmimai

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2026-04-02 19:24; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2026-04-02 19:20; UTC

Rinkos pokalbiai

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2026-04-02 19:01; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2026-04-02 19:00; UTC

Įsigijimai, susijungimai, perėmimai

Union Pacific: Agreement Reached With American Train Dispatchers Association

2026-04-02 18:24; UTC

Įsigijimai, susijungimai, perėmimai

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2026-04-02 17:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2026-04-02 17:32; UTC

Svarbiausios naujienos

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2026-04-02 17:26; UTC

Uždarbis

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2026-04-02 17:17; UTC

Rinkos pokalbiai

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2026-04-02 17:09; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ionis Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

29.95% į viršų

12 mėnesių prognozė

Vidutinis 97.19 USD 29.95%

Aukščiausias 120 USD

Žemiausias 72 USD

Remiantis 14 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ionis Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

14 ratings

Pirkti

Laikyti

Parduoti

Remiantis 14 analitikų, pateikusių Ionis Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.78 / 33.645Palaikymas ir pasipriešinimas

The bullish and bearish events are balanced.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

166 / 349 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.